Drugs / caficrestat
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01731093 | Mar 2012 → Oct 2013 | disorder of defective peroxisome oxidative status | Alltech Life Sciences Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04365699 | Apr 2020 → Jan 2021 | COVID-19 | NYU Langone Health | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04083339 | Sep 2019 → Dec 2023 overdue | cardiomyopathy | Applied Therapeutics, Inc. | Active not recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-12 | Nacuity Pharmaceuticals, Inc. | Regulatory Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA nacuity.com ↗
EMA approved clinical trial of AT-001 (NPI-001) in Iceland |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-12 | Nacuity Pharmaceuticals, Inc. | Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA nacuity.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | caficrestat | “The study team hypothesizes that aldose reductase inhibition with AT-001 (caficrestat) might represent a novel therapeutic approach to reduce inflammation and risk of adverse...” NCT04365699 ↗ |
| Known as | Aldose reductase-in-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297455 ↗ |
| Known as | AT001 | “At present AT001 is the sole name for the active substance.” NCT04083339 ↗ |
| Action | Inhibit | “a highly selective aldose reductase inhibitor” PMID 38597864 ↗ Apr 20241“Aldose reductase inhibitor” CHEMBL4297455 ↗ |
| Modality | Small molecule | — CHEMBL4297455 ↗ |
| Route | Oral | “Mode of Administration: Oral” NCT04365699 ↗ |
| Target | AKR1B1 | “Aldose reductase inhibitor” CHEMBL4297455 ↗ |